Long-Term Cholinesterase Inhibitor Treatment of Alzheimer???s Disease
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 18 (12) , 757-768
Abstract
The most prevalent cause of dementia — Alzheimer’s disease — is characterised by an early cholinergic deficit that is in part responsible for the cognitive deficits, especially memory and attention...Keywords
This publication has 66 references indexed in Scilit:
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004
- Discontinuation syndrome following donepezil cessationInternational Journal of Geriatric Psychiatry, 2003
- Galantamine Provides Sustained Benefits in Patients with ‘Advanced Moderate’ Alzheimer’s Disease for at Least 12 MonthsDementia and Geriatric Cognitive Disorders, 2003
- Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase InhibitorsClinical Pharmacokinetics, 2002
- Selective Inhibitors of ButyrylcholinesteraseDrugs & Aging, 2001
- A comparison of the random-effects pattern mixture model with last-observation-carried-forward(locf) analysis in longitudinal clinical trials with dropoutsJournal of Biopharmaceutical Statistics, 1998
- Recovery of Cognitive Function After StrokeStroke, 1996
- The Neuropsychiatric InventoryNeurology, 1994
- TacrineDrugs & Aging, 1994
- The effects of physostigmine on acetylcholinesterase activity of CSF, plasma and brain. A comparison of intravenous and intra ventricular administration in beagle dogsNeuropharmacology, 1986